Gene Therapy in Rare Respiratory Diseases: What Have We Learned So Far?

• Published in: Journal of clinical medicine Vol. 9; no. 8; p. 2577
• Main Authors: Bañuls, Lucía, Pellicer, Daniel, Castillo, Silvia, Navarro-García, María Mercedes, Magallón, María, González, Cruz, Dasí, Francisco
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 08.08.2020; MDPI
• Subjects: Clinical medicine; Clinical trials; CRISPR; Cystic fibrosis; Gene expression; Gene therapy; Genetic engineering; Genome editing; Genomes; Immune system; Lungs; Mutation; Respiratory diseases; Review; Vectors (Biology); Viruses; gene therapy; alpha-1-antitrypsin deficit; rare respiratory diseases; cystic fibrosis; primary ciliary dyskinesia
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm9082577

Gene therapy is an alternative therapy in many respiratory diseases with genetic origin and currently without curative treatment. After five decades of progress, many different vectors and gene editing tools for genetic engineering are now available. However, we are still a long way from achieving a safe and efficient approach to gene therapy application in clinical practice. Here, we review three of the most common rare respiratory conditions—cystic fibrosis (CF), alpha-1 antitrypsin deficiency (AATD), and primary ciliary dyskinesia (PCD)—alongside attempts to develop genetic treatment for these diseases. Since the 1990s, gene augmentation therapy has been applied in multiple clinical trials targeting CF and AATD, especially using adeno-associated viral vectors, resulting in a good safety profile but with low efficacy in protein expression. Other strategies, such as non-viral vectors and more recently gene editing tools, have also been used to address these diseases in pre-clinical studies. The first gene therapy approach in PCD was in 2009 when a lentiviral transduction was performed to restore gene expression in vitro; since then, transcription activator-like effector nucleases (TALEN) technology has also been applied in primary cell culture. Gene therapy is an encouraging alternative treatment for these respiratory diseases; however, more research is needed to ensure treatment safety and efficacy.